Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
December 28th, 2017
12.1K views
This study implemented whole genome sequencing for analysis of mutations in genes conferring antifungal drug resistance in Candida glabrata. C. glabrata isolates resistant to echinocandins, azoles and 5-flucytosine, were sequenced to illustrate the methodology. Susceptibility profiles of the isolates correlated with presence or absence of specific mutation patterns in genes.
Overview
This study implements whole genome sequencing to identify mutations in genes that confer antifungal drug resistance in Candida glabrata. The methodology illustrates how sequencing can correlate susceptibility profiles of isolates with specific mutation patterns.
Key Study Components
Area of Science
- Microbiology
- Genomics
- Antifungal Resistance
Background
- Candida glabrata is a significant pathogen in fungal infections.
- Understanding genetic mutations can help in diagnosing antifungal resistance.
- Whole genome sequencing provides a comprehensive view of genetic variations.
- Monitoring outbreaks and transmission events is crucial in healthcare settings.
Purpose of Study
- To implement whole genome sequencing in a diagnostic laboratory.
- To identify mutations associated with antifungal drug resistance.
- To enhance detection and monitoring of drug-resistant fungal strains.
Methods Used
- Preparation of genomic DNA samples from clinical and commercial strains.
- Whole genome sequencing of Candida glabrata isolates.
- Analysis of mutation patterns related to drug resistance.
- Correlation of susceptibility profiles with genetic data.
Main Results
- Identification of specific mutations linked to antifungal resistance.
- Demonstration of the sequencing methodology's effectiveness.
- Correlation between genetic mutations and susceptibility profiles.
- Potential for improved outbreak monitoring in healthcare settings.
Conclusions
- Whole genome sequencing is a valuable tool for identifying antifungal resistance.
- Genetic analysis can inform clinical decisions regarding treatment.
- Further research is needed to explore the implications of identified mutations.
Frequently Asked Questions
What is the significance of Candida glabrata?
Candida glabrata is a major fungal pathogen that can cause serious infections, particularly in immunocompromised patients.
How does whole genome sequencing help in antifungal resistance?
It allows for the identification of genetic mutations that confer resistance, aiding in diagnosis and treatment decisions.
What are the main antifungal agents mentioned?
Echinocandins, azoles, and 5-flucytosine are key antifungal agents analyzed in this study.
Who conducted the study?
The study was conducted by Dr. Rebecca Rockett and Dr. Verlaine Timms, doctoral research fellows.
What is the potential impact of this research?
This research could improve the detection and management of antifungal resistance in clinical settings.
How can this study contribute to outbreak monitoring?
By identifying genetic mutations, it can help track transmission events and emerging resistant strains.
Executive Industry Relevance
Whole genome sequencing (WGS) enables comprehensive detection of genetic markers associated with antifungal resistance in Candida glabrata, supporting early identification of resistance mechanisms. This approach reduces reliance on multiple PCR-based assays and provides a scalable solution for clinical laboratories seeking to correlate genotypic changes with phenotypic susceptibility. By identifying mutations in genes such as FKS1, FKS2, CgPDR1, CgCDR1, and FCY2, WGS enhances predictive confidence in antifungal susceptibility testing and informs therapeutic decision-making.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by linking specific SNPs in antifungal resistance genes to elevated minimum inhibitory concentrations.
- Operational Value: Supports biological de-risking through genome-wide identification of resistance-conferring mutations without prior knowledge of target loci.
- Predictive Value: Facilitates mechanistic de-risking by validating genotype-phenotype correlations across azole, echinocandin, and 5-flucytosine resistance pathways.
Screening & Assay Development
- Assay Readiness: Provides standardized, reproducible workflows for preparing normalized sequencing libraries from clinical Candida glabrata isolates.
- Quantitative Output: Delivers high-depth coverage (~75-fold) and high mapping rates (~98%) enabling reliable detection of single nucleotide polymorphisms.
- Scalability: Demonstrates turnaround time and cost comparable to Sanger sequencing, supporting implementation in diagnostic and research settings.
Translational & Preclinical Research
- Disease Relevance: Uses clinical isolate pairs showing resistance development during antifungal therapy to model acquired resistance in vivo.
- Translational Continuity: Bridges in vitro susceptibility testing with genotypic confirmation, supporting risk-adjusted advancement decisions in antifungal development.
- Biomarker Alignment: Identifies non-synonymous SNPs in resistance genes (e.g., FCY2 for 5-flucytosine, FKS1/FKS2 for echinocandins) as potential translational biomarkers.
Pipeline & Workflow Integration
WGS integrates into the antifungal discovery continuum by enabling hypothesis-free detection of resistance mechanisms during lead optimization and preclinical evaluation, particularly when phenotypic resistance emerges.
- Discovery Biology: Supports hypothesis testing and pathway clarification by correlating SNP patterns with drug class-specific resistance phenotypes.
- Screening: Enhances assay readiness through standardized DNA library preparation and quality control checkpoints for reproducible sequencing outcomes.
- Analytics: Enables quantitative comparison of mutation frequencies and genomic coverage across isolates, supporting data-driven strain selection.
- Translational Research: Connects genotypic findings to clinical resistance patterns, informing preclinical model selection and biomarker strategy.
- Enterprise Reuse: Establishes a reusable genomic capability for surveillance of resistance emergence across fungal species and antifungal classes.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by confirming resistance mechanisms through direct genetic evidence.
- Operational Value: Improves standardization and reproducibility via defined quality control points in DNA extraction, library normalization, and sequencing preparation.
- Strategic Value: Reduces late-stage biological risk by enabling early detection of resistance-conferring mutations during preclinical screening.
- Portfolio Impact: Supports risk-adjusted prioritization by identifying strains with confirmed genotypic resistance profiles for exclusion or mechanistic follow-up.
Implementation Considerations
- Requires expertise in fungal genomics, next-generation sequencing library preparation, and bioinformatic analysis of SNP variants.
- Depends on access to sequencing platforms, magnetic bead-based cleanup systems, and thermal cyclers for tagmentation and indexing steps.
- Necessitates cross-team standardization between microbiology and genomics teams for sample tracking, metadata annotation, and variant interpretation.
- Involves adaptation considerations for different Candida glabrata strain backgrounds and varying DNA quality from clinical isolates.
- Includes practical limitations such as the need for sufficient DNA input and potential challenges in analyzing complex genomic regions or structural variations.
Biopharma FAQs
Why is SNP confirmation important for target validation in antifungal resistance?
Confirming single nucleotide polymorphisms in genes like FKS1 and FCY2 through WGS provides direct genetic evidence linking specific mutations to elevated MIC values, supporting mechanistic validation of resistance targets.
How does isolating the independent variable of genetic background improve discovery pipeline accuracy?
By comparing isogenic isolate pairs before and after antifungal exposure, the study controls for genetic background, enabling clearer attribution of resistance development to acquired mutations rather than strain variability.
What quantitative dependent variable measurements enable resistance detection in this WGS approach?
The approach relies on measuring minimum inhibitory concentration (MIC) as the phenotypic dependent variable, which is correlated with the presence of specific SNPs identified through WGS as the independent genetic variable.
Why do replication requirements matter for cross-functional collaboration in resistance testing?
Replication across isolate pairs and consistent SNP-phenotype correlation ensure reliability, allowing microbiology and genomics teams to align on resistance interpretation and build confidence in shared datasets.
What statistical analysis capabilities are required before implementing WGS for resistance marker detection?
Implementation requires bioinformatic pipelines capable of read mapping, variant calling, and filtering for non-synonymous SNPs in known resistance genes, supported by quality metrics like >75-fold coverage and >98% mapping rate.
